Pharmacokinetic modeling of [11C]flumazenil kinetics in the rat brain
© The Author(s). 2017
Received: 17 December 2016
Accepted: 15 February 2017
Published: 22 February 2017
Preferred models for the pharmacokinetic analysis of [11C]flumazenil human studies have been previously established. However, direct translation of these models and settings to animal studies might be sub-optimal. Therefore, this study evaluates pharmacokinetic models for the quantification of [11C]flumazenil binding in the rat brain.
Dynamic (60 min) [11C]flumazenil brain PET scans were performed in two groups of male Wistar rats (tracer dose (TD), n = 10 and pre-saturated (PS), n = 2). Time-activity curves from five regions were analyzed, including the pons (pseudo-reference region). Distribution volume (VT) was calculated using one- and two-tissue compartment models (1TCM and 2TCM) and spectral analysis (SA). Binding potential (BPND) was determined from full and simplified reference tissue models with one or two compartments for the reference tissue (FRTM, SRTM, and SRTM-2C). Model preference was determined by Akaike information criterion (AIC), while parameter agreement was assessed by linear regression, repeated measurements ANOVA and Bland-Altman plots.
1TCM and 2TCM fits of regions with high specific binding showed similar AIC, a preference for the 1TCM, and good VT agreement (0.1% difference). In contrast, the 2TCM was markedly preferred and necessary for fitting low specific-binding regions, where a worse VT agreement (17.6% difference) and significant VT differences between the models (p < 0.005) were seen. The PS group displayed results similar to those of low specific-binding regions. All reference models (FRTM, SRTM, and SRTM-2C) resulted in at least 13% underestimation of BPND.
Although the 1TCM was sufficient for the quantification of high specific-binding regions, the 2TCM was found to be the most adequate for the quantification of [11C]flumazenil in the rat brain based on (1) higher fit quality, (2) lower AIC values, and (3) ability to provide reliable fits for all regions. Reference models resulted in negatively biased BPND and were affected by specific binding in the pons of the rat.
Keywords[11C]Flumazenil Pharmacokinetic modeling Rat GABAA receptors PET
[11C]Flumazenil is a well-established and widely used radiotracer in positron emission tomography (PET) studies in humans  as a GABAA antagonist. It binds to the benzodiazepine binding site of the GABAA receptor, allowing PET imaging of [11C]flumazenil uptake to enable the in vivo visualization and quantification of processes related to neuronal loss and integrity [2, 3]. More specifically, flumazenil displays comparable levels of binding to the GABAA receptors containing α1, α2, α3, or α5 subunits, which is why this compound is considered to be not subtype-selective . For these reasons, [11C]flumazenil can be considered a versatile PET tracer and it has been used in the study and assessment of several conditions, such as neuronal damage in head injury , epilepsy , stroke-induced penumbral areas of infarction , and Alzheimer’s disease .
The quantification of [11C]flumazenil uptake and binding is often performed by pharmacokinetic modeling, with the aid of compartmental models . For the application of those models, information on tracer delivery is needed. This information can be obtained either in a direct form, by arterial sampling and the construction of a plasma input function, or in an indirect manner making use of a reference tissue devoid of receptors of interest . Previous human studies [11, 12] evaluated the performance of some of these models (plasma input and reference tissue based) and established which ones provided a more robust and reliable quantification of [11C]flumazenil receptor binding. For plasma input methods, the one tissue compartment model (1TCM) was determined to be the preferred model . Among the reference-based models for [11C]flumazenil quantification, the simplified reference tissue model (SRTM) was considered valid and robust , with the use of the pons as the reference tissue, based on the fact that this region shows a low density of GABAA receptors .
However, the superiority, validity, and accuracy of the 1TCM and the SRTM for the quantification of [11C]flumazenil binding have only been assessed in human studies and, therefore, are related to the behavior of this radiotracer in the human brain. Surprisingly, there has not yet been a careful assessment of the performance of the different pharmacokinetic models for rat studies. Nonetheless, pharmacokinetic modeling can be of particular relevance in the pre-clinical setting, since animal studies are often applied in drug development, longitudinal disease monitoring, or treatment response assessment. There, assessing the full tracer kinetic profile in tissue is preferable above semi-quantitative measures such as standard uptake values (SUVs) or SUV ratios (SUVR) [15, 16]. Since anatomical and physiological variations between species can affect tracer kinetics, the suitability of the clinically appropriate kinetic models for [11C]flumazenil brain kinetics can be questioned. Therefore, the purpose of this study was to investigate which pharmacokinetic model is most appropriate for the quantification of [11C]flumazenil binding in pre-clinical rat studies. In order to do so, we retrospectively analyzed PET rat brain data, as well as simulated data, by a number of different methods, including compartmental (plasma input and reference tissue based) and non-compartmental methods.
Overview of the animal groups, injected activity, and mass. Data are expressed as mean ± SD
Tracer dose (n = 10)
59.3 ± 22.6
3.3 ± 2.4
0.273 ± 0.03
Pre-saturated (n = 2)
71.9 and 59.1
1.9 and 5.6
0.300 and 0.295
All animal experiments were performed according to the Dutch Law on Animal Experiments and approved by the Institutional Animal Care and Use Committee of the University of Groningen (6264B).
Animals were anesthetized with 5% isoflurane (maintained at 1.5–2.0%) mixed with medical air with 1.5–2 ml/min flow. Next, animals were positioned in the PET camera (Focus 220, Siemens Medical Solutions, USA) with the head in the field of view and in trans-axial position. After a point-source (Co-57) transmission scan, an automatic pump was used for the bolus injection of [11C]flumazenil over 60s. Dynamic PET data were acquired in list mode for 60 min, starting from the moment the tracer entered the body. For the PS group, unlabeled flumazenil (330 nmol in 200 μl of 15% ethanol in saline) was injected intravenously 5 min before tracer administration .
The precursor of [11C]flumazenil and the cold flumazenil were obtained from ABX (art. 1700 and 1710, respectively) in order to ensure high chemical purity (>95%). The labeled [11C]flumazenil was then synthesized in our laboratory at the UMCG as described elsewhere . Moreover, the cold flumazenil compound was used as standard for the HPLC settings for both the radiotracer synthesis and for the metabolite analysis. It was also the compound used for the pre-saturation of the PS group.
List-mode data was reconstructed into 21 frames (6 × 10, 4 × 30, 2 × 60, 1 × 120, 1 × 180, 4 × 300 and 3 × 600 s) including all necessary corrections to obtain quantitative emission images. Sinograms were Fourier rebinned and reconstructed by a 2D-OSEM algorithm  with 4 iterations and 16 subsets, resulting in 128 × 128 × 95 matrix images, with 0.63 mm pixel width and 0.79 mm slice thickness. All subsequent PET image analysis, including pharmacokinetic modeling, was performed with PMOD v3.7 (PMOD Technologies Ltd., Switzerland).
Individual dynamic images were automatically coregistered to a [11C]flumazenil template  pre-aligned to the Paxinos stereotaxic coordinates system. Bilateral volumes of interest (VOIs) were extracted from a set of previously constructed regions , including the whole brain and regions with high GABAA expression (the frontal cortex and the hippocampus), and low GABAA expression (cerebellum, medulla, and pons). Due to their small size and potential vulnerability to spillover effects, the VOIs from medulla and pons were adapted and reduced in order to further separate them from neighboring high tracer uptake regions. Finally, time-activity curves (TACs) were generated by projecting the pre-defined VOIs onto the dynamic images.
Determination of individual metabolite corrected plasma input curves
For the determination of a metabolite corrected plasma input function, arterial blood samples of 0.1 ml were acquired (n = 16) and for 2–3 of the time points, larger samples (0.6 ml) were collected for metabolite analysis. These 2-3 time points were collected at 5, 10, 15, 30, 45 or 60 min post injection, in order to adequately sample the metabolites dynamics. Equivalent volumes of saline were injected to avoid a decrease in blood pressure. For each sample, blood and plasma were separated and measured in a gamma counter (LKB-Wallac, Finland) for the construction of both blood and plasma input curves.
The metabolites were determined by first diluting the plasma with an equivalent volume of acetonitrile and mixing it with a vortex for 1 min. Next, it was centrifuged at 5.300 rpm for 3 min. The supernatant was then filtered through a Millipore filter (Millex-HV 4 mm syringe filter, pore 0.45 μm) and an equivalent volume of water was added, and the volume adjusted to 1 ml with an HPLC mobile phase. The resulting solution was analyzed by HPLC using an Alltima RP-C18 column (5 μm, 10 × 250 mm) and a mobile phase of acetonitrile/1 mM H3PO4 (25/75) at a flow of 5 ml/min.
Next, a population metabolite curve was constructed by averaging the metabolite samples of the individual rats and fitting the average curve with a single-exponential function. Finally, the population average metabolite curve was used for the metabolite correction of the individual plasma input functions.
Plasma input models included the one- and two-tissue compartment models (1TCM and 2TCM, respectively), and the spectral analysis (SA) . The SA method was applied with 50 basis functions, the minimum exponential coefficient set to 0.001 s−1, and the maximum exponential coefficient to 1 s−1. The range of exponential coefficients was determined based on (1) the range of VT obtained from 1TCM and 2TCM and (2) the suggested limits of upper and lower bounds as described previously [25, 26]. The number of grid components (50) was chosen in order to balance good coverage of basis functions and computational efficiency. Model fits were performed with individual metabolite corrected plasma curves as input functions and a fixed blood volume fraction of 5% of the whole blood curve. Blood delay was calculated for the whole brain and subsequently fixed for the remaining regions. The distribution volume (VT) was the parameter of interest for all plasma input models.
Following previous studies, the pons was considered as the reference region and its TAC served as input function for the reference-based models. The full reference tissue model (FRTM) and two versions of the simplified reference tissue model, with either one (SRTM) or two (SRTM-2C) compartments for the reference region, were applied to the data. The parameter of interest for the reference tissue-based models was the non-displaceable binding potential (BPND).
Finally, BPND was also indirectly determined from the VT estimates of the plasma input models (BPND = (VT/VT reference)–1 = DVR–1)  for method comparison.
Overview of the micro and macro parameters used for the simulated TACs
(K1/k2) × [1 + (k3/k4) + (k5/k6)]
The simulated TACs were subsequently analyzed with the same models used for the animal data. VT and BPND from simulated data were compared to the theoretical values derived from the 3TCM configuration (Table 2). Model preference was assessed for the noiseless TACs, as well as for the different noise levels.
Model comparison and statistical analysis
Statistical data analysis was performed with IBM SPSS Statistics 22 for both animal and simulated data, and the results are presented as mean ± standard deviation (SD).
Model preference between 1TCM and 2TCM was assessed for each region based on the Akaike information criterion (AIC) . Regional differences in VT values estimated from the three different models (1TCM, 2TCM, and SA) were tested for significance by repeated measures ANOVA and subsequent paired t tests. Parameter estimates were also compared between all the six models by linear regression analysis and Bland-Altman plots. All results were considered significant when p < 0.05 and, whenever suited, subsequently corrected for multiple comparisons by applying the Bonferroni-Holm correction.
Data from the PS group was excluded from the linear regression analysis. This was done in order to avoid two clear clusters of different VT magnitudes in the linear plot, which could affect the correlation values.
Following the AIC results, the 2TCM VT were considered as reference values for model comparison as it was the model which provided reliable fits across all brain regions.
Regional distribution volume (VT) estimates from the three different methods for each of the groups. Data are expressed as mean ± SD for the tracer dose group (n = 10) and as individual values for the pre-saturated group (n = 2)
Tracer dose (n = 10)
7.81 ± 1.10
7.80 ± 2.38
7.15 ± 1.17
6.86 ± 0.94
6.84 ± 2.08
6.55 ± 0.95
4.44 ± 0.67
4.11 ± 1.24
4.33 ± 0.65
2.77 ± 0.48
2.35 ± 0.71
2.66 ± 0.39
2.54 ± 0.40
2.10 ± 0.61
2.45 ± 0.33
Pre-saturated (n = 2)
1.23 and 1.10
0.67 and 0.73
1.00 and 0.89
1.07 and 0.92
0.60 and 0.62
1.09 and 0.68
0.98 and 0.91
0.52 and 0.58
1.00 and 0.69
0.89 and 0.80
0.46 and 0.56
0.69 and 0.83
0.99 and 0.88
0.55 and 0.59
0.80 and 0.72
Bland-Altman analysis of VT, DVR–1 and BPND of animal data
% difference (95% L.A.)
−0.20 (−1.93 to 1.52)
−5.16 (−18.2 to 7.87)
−0.32 (−2.50 to 1.84)
−1.43 (−10.0 to 7.15)
−8.01 (−19.0 to 3.01)
−1.31 (−5.42 to 2.78)
−16.9 (−34.0 to 0.24)
−3.54 (−14.4 to 7.32)
−19.1 (−35.9 to −2.37)
0.44 (−24.2 to 25.0)
−8.91 (−28.4 to 10.5)
−2.20 (−16.2 to 11.8)
26.7 (4.74 to 48.7)
−9.01 (−53.3 to 35.3)
28.3 (5.72 to 50.8)
−2.53 (−31.5 to 26.4)
24.1 (4.75 to 43.2)
1.70 (−22.8 to 26.2)
28.5 (−44.7 to 101)
−7.02 (−49.3 to 35.3)
26.9 (−12.6 to 66.4)
−4.21 (−39.8 to 31.4)
−12.5 (−20.3 to −4.67)
−13.8 (−21.5 to 6.16)
−7.74 (−15.3 to −0.22)
−11.0 (−17.9 to −4.05)
−12.5 (−19.6 to −5.40)
−7.59 (−12.9 to −2.24)
−6.54 (−15.9 to 2.82)
−9.58 (−22.3 to 3.14)
−13.7 (−29.1 to 1.72)
−25.6 (−152 to 101)
−27.7 (−134 to 78.8)
−66.2 (−151 to 18.8)
−13.9 (−76.7 to 48.9)
−15.9 (−69.6 to 37.8)
−23.8 (−88.0 to 40.4)
Indirect and direct binding potential
Regional binding potential (BPND or DVR–1) estimates from the different methods for the tracer dose group (n = 10). Data are expressed as mean ± SD
2.09 ± 0.23
2.75 ± 0.36
1.94 ± 0.42
1.84 ± 0.20
1.92 ± 0.20
1.93 ± 0.20
1.71 ± 0.21
2.28 ± 0.26
1.69 ± 0.32
1.53 ± 0.19
1.51 ± 0.19
1.59 ± 0.18
0.75 ± 0.08
0.96 ± 0.14
0.77 ± 0.11
0.70 ± 0.07
0.68 ± 0.08
0.65 ± 0.08
0.09 ± 0.03
0.12 ± 0.03
0.08 ± 0.03
0.08 ± 0.07
0.07 ± 0.04
0.05 ± 0.03
Compared to the other models, 1TCM DVR–1 showed the largest overall difference to 2TCM DVR–1 values (26.9%), with 95% limits of agreement reaching more than 40% for all regions (Table 4). Estimates of DVR–1 from SA demonstrated an overall small difference to 2TCM DVR–1 values (−4.21%) but with wide 95% limits of agreement (−39.8 to 31.37%), indicating an overall higher variability in parameter estimation (Fig. 6). All reference models (FRTM, SRTM, and SRTM-2C) underestimated BPND (differences of −13.9, −15.9, and −23.8%, respectively) in comparison with DVR–1 from the 2TCM.
Simulated data exhibited a similar pattern in the Bland-Altman plot (Fig. 7b). FRTM, SRTM, and SRTM-2C resulted in an underestimation of BPND, with a (negative) bias (−0.75, −1.03, and −0.88%, respectively) that showed a slight increase for higher levels of binding (larger k3). SA displayed negligible bias (0.14%), independent of the binding level. DVR–1 from both the 1TCM and the 2TCM resulted in a positive bias, with 40.5% BPND overestimation for the 1TCM and a 5.6% overestimation for the 2TCM.
The 1TCM and the SRTM were previously established as methods of choice for the quantification of [11C]flumazenil in human studies . Since a direct translation from the clinical to the pre-clinical setting, or vice-versa, is not recommendable, an assessment must be performed to determine whether the clinically used 1TCM and SRTM are also suited for the analysis of [11C]flumazenil in animal studies. Therefore, the present study evaluated different pharmacokinetic models for the quantification of [11C]flumazenil binding specifically for the rat brain.
The distribution pattern seen in the TD group was comparable to what was seen in human studies, as well as autoradiography studies of the rat brain [20, 30], displaying higher uptake in the cortical regions and the lowest in pons and medulla. However, it is interesting to note that the VT in the pons was more than two times higher than what has been reported in human studies [13, 31]. In fact, both medulla and pons of the TD group exhibited a relatively high VT (VT > 2) for low-density regions, independently of the model used for quantification. Since these high VT values could have been related to spillover effects from neighboring regions, the delineation of pons and medulla VOIs from the original atlas was limited in order to further separate the regions and minimize the potential spillover. Moreover, pre-saturation with cold flumazenil resulted in a clear decrease of the VT in the pons of approximately 35%, as compared with the VT values observed in the TD group. These results suggest the presence of a substantial level of specific binding in the rat pons, which is in line with a considerable displacement of a fluorinated version of flumazenil in that region, reported in a study by Dedeurwaerdere et al. . For this reason, the pons cannot be considered a “true reference region” in rat studies, and the estimation of BPND from the reference tissue-based models are negatively biased.
In terms of model preference, regions with high density of GABAA receptors (frontal cortex and hippocampus) followed the same behavior as what has been described in humans. These regions showed a strong (70%) preference for the 1TCM according to AIC and in accordance with the spectra of SA analysis. However, a closer look into the results suggests that the 2TCM resulted in similar AIC values (e.g., 143.7 ± 7.1 for the 1TCM against 144.8 ± 9.6 for the 2TCM in the frontal cortex), with both models providing similar VT values. In fact, no statistical differences were found between 1TCM and 2TCM VT values for those regions. Such findings are in line with what has previously been reported for human studies , where the authors state that expanding from a 1TCM to a 2TCM configuration did not improve the quality of the fit in high-density regions. These observations could be explained by the relative size between specific and non-specific compartments for these regions. In the presence of high levels of binding, the contribution of the non-specific component to the overall signal becomes too small, and the two compartments cannot be kinetically distinguished. Our results suggest that the 1TCM could be applied for these regions due to its reduced complexity compared to the 2TCM, despite the fact that both models provide similar AIC, VT, and BPND values. However, applying the same model to all regions of interest is advisable. In that way, potential individual or group differences in estimated parameters are not affected by differences in model choice and would therefore better represent any underlying physiological changes. Thus, the decision as to which of the two models (1TCM and 2TCM) should be applied must also incorporate the performance of these models for the low-density regions.
Indeed, one important finding of this study was the observation that the 1TCM is not suited for the quantification of low-density regions. The first indication is the preference displayed by these regions for the 2TCM, supported by AIC values, visual inspection of TAC fits (Fig. 3a, b), and kinetic spectra from SA. In fact, especially for the pons, the 1TCM was not preferred for any of the animals of the TD group. Moreover, VT values were significantly different between models for low-binding regions, demonstrating that the various models cannot be used interchangeably in this case. Instead, the 2TCM provided the best fits, while the 1TCM consistently underestimated VT compared to those from 2TCM. While the SA provided VT values similar to those from 2TCM, the difference between the methods was still statistically significant and the standard deviation observed in this method was the largest of the three. This variability in the VT estimates could be explained by the known sensitivity of this method to noise , but it could also be related to the wide definition of the basis function settings used in the study. Therefore, based on the present results, SA should be considered carefully for the analysis of rat data. It is interesting to notice, however, the intermediate behavior displayed by cerebellum in terms of model performance. In this region, although the model preference based on AIC strongly favored the 2TCM, differences between 1TCM or SA and 2TCM-derived VT values were not so marked. This could be related to the intermediate levels of α subunits in this region .
Regarding the PS group, the analysis of model preference and performance produced results similar to those of the low-density regions, with lower AIC values for the 2TCM. These results were surprising, as the pre-saturation was expected to completely block the second (specific) compartment  and to leave only the first compartment intact (i.e., the compartment related to the free and non-displaceable components). Due to the similarity in model preference between PS group and low-density regions of the TD group, it was hypothesized that model preference is affected by the levels of specific binding present in a particular region. Therefore, simulated data were generated in order to substantiate this hypothesis, and the results obtained from the analysis seemed to support it. More specifically, both the 1TCM and the 2TCM showed good agreement to theoretical values for TACs with high VT, and the bias increased for TACs with lower VT. Moreover, the TACs with high binding and therefore high VT values showed smaller differences in AIC between 1TCM and 2TCM fits, while this difference increased for lower VT values. The differences in model preference and performance seen between the simulated and the animal datasets can be explained by the noiseless character of the generated TACs.
As previously mentioned, the rat pons demonstrated a considerable level of specific binding. Coupled with the underestimation in VT seen from the 1TCM, these results could explain the poor performance of reference models. First, the specific binding seen in the pons results in an underestimation of BPND by direct estimation based on reference models. Second, the fact that the pons is better described by a 2TCM directly violates one of the assumptions used in the FRTM and SRTM, where the reference region should be adequately described by a 1TCM configuration . Our results confirmed the violation of this assumption, and both SRTM and FRTM were affected in a similar way, displaying similar differences in BPND estimates as compared to DVR–1 from the 2TCM. Such an effect has larger impact for high-binding regions and results in considerable underestimation of BPND in absolute terms . In order to allow a different configuration for the reference tissue, the SRTM-2C was also tested. Interestingly, the SRTM-2C showed a small improvement compared to the other reference models for high-binding regions (Table 3). Indeed, fits of those regions showed lower AIC values for the SRTM-2C compared to the SRTM (data not shown). However, the 2TCM-2C resulted in larger differences to 2TCM DVR–1 for cerebellum and medulla, which could be due to a combination between low amounts of specific binding and the larger number of model parameters, resulting in increased uncertainty in parameter estimation. In that context, SRTM represented the most robust reference model for the animal data. Yet, it should be mentioned that both plasma input-derived DVR–1 and SRTM-based BPND estimates will be negatively biased by the presence of specific binding in the reference region (pons), as discussed below. Moreover, it is also important to notice that although radiometabolites have the potential to introduce bias in estimation of model parameters, the reported major metabolites of [11C]flumazenil are polar compounds and, as such, are expected not to enter the brain .
In summary, the quantification of [11C]flumazenil binding in rat studies should not be performed with the 1TCM, as it is the case in human studies. In fact, the 2TCM is required for an accurate VT estimation in low-density regions such as the pons, and it provides VT values equivalent to 1TCM for the high-density regions. In the case of reference-based modeling, the use of the pons as a reference region requires careful consideration. Since the rat pons demonstrated a considerable level of specific binding, any direct estimation of BPND via reference models will suffer from underestimation of tracer binding. However, the pons might be considered a pseudo-reference region , provided the experimental conditions and physiological state of the animals does not affect tracer delivery and binding in this region across the different groups. Such a condition might not be met for different study designs. In those cases, a first validation using plasma input kinetic analysis in a subsample of the data is required in order to ensure that pons could be used as pseudo-reference region. Once the pons has been validated as a pseudo-reference region, reference-based modeling could be useful in providing a simple and robust alternative for BPND estimation without arterial sampling. In that case, SRTM would be preferable due to its robust implementation, smaller number of fit parameters, and good agreement to DVR–1 from the 2TCM.
This study showed that [11C]flumazenil kinetics is different between rats and humans, and indicate that kinetic models used in clinical studies are not necessarily suited in the pre-clinical setting. For high-density regions, both 1TCM and 2TCM estimated comparable VT values and resulted in similar quality of fits (AIC). However, the application of the 2TCM in low-density regions resulted in higher quality of fits, both from visual inspection and AIC values. Moreover, the clinically applied 1TCM was not able to satisfactorily fit the data (visual inspection) of those regions, nor in the case of pre-saturation with cold flumazenil. Therefore, the 2TCM is the preferred plasma input model for the quantification of [11C]flumazenil in the rat brain. Among the various reference tissue models tested, SRTM was preferred providing BPND estimates in good agreement with plasma input 2TCM based DVR–1 values.
The scholarship of Andrea Parente was financed by Siemens. The other authors declare no conflict of interest.
ILA and RB jointly developed the concept and design of the manuscript. AP and JD were responsible for the experimental design and data collection. MK and AW greatly contributed to the methodology and discussion of the findings. DVG was involved in the data analysis and strongly contributed to the discussion of the results. AMMdS and RD added important points to the discussion. ILA wrote the first draft, and all previously mentioned co-authors critically reviewed and edited the original and every subsequent draft. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
All animal experiments were performed according to the Dutch Law on Animal Experiments and approved by the Institutional Animal Care and Use Committee of the University of Groningen (6264B).
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
- Odano I, Halldin C, Karlsson P, Varrone A, Airaksinen AJ, Krasikova RN, et al. [18 F]Flumazenil binding to central benzodiazepine receptor studies by PET. Neuroimage [Internet]. Elsevier Inc.; 2009. 45(3):891–902. Available from: http://dx.doi.org/https://doi.org/10.1016/j.neuroimage.2008.12.005
- Heiss WD, Grond M, Thiel A, Ghaemi M, Sobesky J, Rudolf J, et al. Permanent cortical damage detected by flumazenil positron emission tomography in acute stroke. Stroke. 1998;29(2):454–61.View ArticlePubMedGoogle Scholar
- Heiss WD, Kracht L, Grond M, Rudolf J, Bauer B, Wienhard K, et al. Early [(11)C]Flumazenil/H(2)O positron emission tomography predicts irreversible ischemic cortical damage in stroke patients receiving acute thrombolytic therapy. Stroke [Internet]. 2000;31(2):366–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10657407.View ArticleGoogle Scholar
- Atack JR, Scott-stevens P, Beech JS, Fryer TD, Hughes JL, Cleij MC, et al. Comparison of lorazepam [7-chloro-5-(2-chlorophenyl)-1,3-dihydro-3-hydroxy-2H-1, 4-benzodiazepin-2-one] occupancy of rat brain gamma—aminobutyric acid a receptors measured using in vivo [3H]flumazenil (8-fluoro 5,6-dihydro-5-methyl-6-oxo-4H-imidaxzo[1. J Pharmacol Exp Ther. 2007;320(3):1030–7.View ArticlePubMedGoogle Scholar
- Geeraerts T, Coles JP, Aigbirhio FI, Pickard JD, Menon DK, Fryer TD, et al. Validation of reference tissue modelling for [11C]flumazenil positron emission tomography following head injury. Ann Nucl Med [Internet]. 2011;25(6):396–405. [cited 2014 Nov 5] Available from: http://www.ncbi.nlm.nih.gov/pubmed/21461598.View ArticleGoogle Scholar
- Lamusuo S, Pitkänen A, Jutila L, Ylinen A, Partanen K, Kälviäinen R, et al. [11 C]Flumazenil binding in the medial temporal lobe in patients with temporal lobe epilepsy: correlation with hippocampal MR volumetry, T2 relaxometry, and neuropathology. Neurology [Internet]. 2000;54(12):2252–60. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10881249.View ArticleGoogle Scholar
- Heiss WD, Sobesky J, Smekal UV, Kracht LW, Lehnhardt FG, Thiel A, et al. Probability of cortical infarction predicted by flumazenil binding and diffusion-weighted imaging signal intensity: a comparative positron emission tomography/magnetic resonance imaging study in early ischemic stroke. Stroke. 2004;35(8):1892–8.View ArticlePubMedGoogle Scholar
- Pascual B, Prieto E, Arbizu J, Marti-Climent JM, Peñuelas I, Quincoces G, et al. Decreased carbon-11-flumazenil binding in early Alzheimer’s disease. Brain [Internet]. 2012;135(Pt 9):2817–25. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22961552.View ArticleGoogle Scholar
- Gunn RN, Gunn SR, Cunningham VJ. Positron emission tomography compartmental models. J Cereb Blood Flow Metab [Internet]. 2001;21(6):635–52. [cited 2014 Jul 21]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/11488533.View ArticleGoogle Scholar
- Millet P, Graf C, Buck A, Walder B, Ibáñez V. Evaluation of the reference tissue models for PET and SPECT benzodiazepine binding parameters. Neuroimage. 2002;17(2):928–42.View ArticlePubMedGoogle Scholar
- Koeppe RA, Holthoff VA, Frey KA, Kilbourn MR, Kuhl DE. Compartmental analysis of [11C]flumazenil kinetics for the estimation of ligand transport rate and receptor distribution using positron emission tomography. J Cereb Blood Flow Metab [Internet]. 1991;11(5):735–44. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1651944.View ArticleGoogle Scholar
- Price JC, Mayberg HS, Dannals RF, Wilson AA, Ravert HT, Sadzot B, et al. Measurement of benzodiazepine receptor number and affinity in humans using tracer kinetic modeling, positron emission tomography, and [11C]flumazenil. J Cereb Blood Flow Metab. 1993;13(4):656–67.View ArticlePubMedGoogle Scholar
- Klumpers UM, Veltman DJ, Boellaard R, Comans EF, Zuketto C, Yaqub M, et al. Comparison of plasma input and reference tissue models for analysing [11C]flumazenil studies. J Cereb Blood Flow Metab [Internet]. 2008;28(3):579–87. [cited 2014 Nov 5]; Available from: http://jcb.sagepub.com/lookup/doi/https://doi.org/10.1038/sj.jcbfm.9600554.View ArticlePubMedGoogle Scholar
- Halldin C, Farde L, Litton J, Hall H, Sedvall G. [11C]Ro 15-4513, a ligand for visualization of benzodiazepine receptor binding. Psychopharmacology (Berl) [Internet]. 1992;108(1–2):16–22. Available from: http://link.springer.com/https://doi.org/10.1007/BF02245279.View ArticleGoogle Scholar
- Hoekzema E, Rojas S, Herance R, Pareto D, Abad S, Jiménez X, et al. In vivo molecular imaging of the GABA/benzodiazepine receptor complex in the aged rat brain. Neurobiol Aging [Internet]. Elsevier Inc.; 2012; 33(7):1457–65. Available from: http://dx.doi.org/https://doi.org/10.1016/j.neurobiolaging.2010.12.006
- Rojas S, Martín A, Pareto D, Herance JR, Abad S, Ruíz A, et al. Positron emission tomography with 11C-flumazenil in the rat shows preservation of binding sites during the acute phase after 2 h-transient focal ischemia. Neuroscience [Internet]. Elsevier Inc.; 2011 May 19;182:208–16. Available from: http://dx.doi.org/https://doi.org/10.1016/j.neuroscience.2011.03.013
- Parente A, Feltes PK, Vallez Garcia D, Sijbesma JWA, Moriguchi Jeckel CM, Dierckx RAJO, et al. Pharmacokinetic analysis of 11C-PBR28 in the rat model of herpes encephalitis: comparison with (R)-11C-PK11195. J Nucl Med. 2016;57(5):785–91.View ArticlePubMedGoogle Scholar
- Vállez García D, de Vries EFJ, Toyohara J, Ishiwata K, Hatano K, Dierckx RAJO, et al. Evaluation of [(11)C]CB184 for imaging and quantification of TSPO overexpression in a rat model of herpes encephalitis. Eur J Nucl Med Mol Imaging. 2015;42(7):1106–18.View ArticlePubMed CentralPubMedGoogle Scholar
- de Vries EFJ, Dierckx RA, Klein HC. Nuclear imaging of inflammation in neurologic and psychiatric disorders. Curr Clin Pharmacol [Internet]. 2006;1(3):229–42. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18666748.View ArticleGoogle Scholar
- Dedeurwaerdere S, Gregoire M-C, Vivash L, Roselt P, Binns D, Fookes C, et al. In-vivo imaging characteristics of two fluorinated flumazenil radiotracers in the rat. Eur J Nucl Med Mol Imaging [Internet]. 2009;36(6):958–65. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19205698.View ArticleGoogle Scholar
- Någren K, Halldin C. Methylation of amide and thiol functions with [11C]methyl triflate, as exemplified by [11C]NMSP[11C]flumazenil and [11C]methionine. J Label Compd Radiopharm. 1998;41(9):831–41.View ArticleGoogle Scholar
- Hudson HM, Larkin RS. Accelerated image reconstruction using ordered subsets of projection data. IEEE Trans Med Imaging [Internet]. 1994;13(4):601–9. Available from: http://ieeexplore.ieee.org/lpdocs/epic03/wrapper.htm?arnumber=363108.View ArticleGoogle Scholar
- Vállez Garcia D, Casteels C, Schwarz AJ, Dierckx RAJO, Koole M, Doorduin J. A standardized method for the construction of tracer specific PET and SPECT rat brain templates: validation and implementation of a toolbox. PLoS One [Internet]. 2015;10(3):e0122363. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25823005.View ArticleGoogle Scholar
- Cunningham VJ, Jones T. Spectral analysis of dynamic PET studies. J Cereb Blood Flow Metab [Internet]. 1993;13(1):15–23. Available from: http://dx.doi.org/https://doi.org/10.1038/jcbfm.1993.5.View ArticleGoogle Scholar
- Turkheimer F, Sokoloff L, Bertoldo A, Lucignani G, Reivich M, Jaggi JL, et al. Estimation of component and parameter distributions in spectral analysis. J Cereb Blood Flow Metab [Internet]. 1998;18(11):1211–22. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9809510.View ArticleGoogle Scholar
- Veronese M, Rizzo G, Bertoldo A, Turkheimer FE. Spectral analysis of dynamic PET studies: a review of 20 years of method developments and applications. Comput Math Methods Med [Internet]. 2016;2016:7187541. Available from: https://www.hindawi.com/journals/cmmm/2016/7187541/.Google Scholar
- Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage [Internet]. 1996;4(3):153–8. [cited 2017 Feb 3]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/9345505.View ArticlePubMedGoogle Scholar
- Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab [Internet]. 2007;27(9):1533–9. Available from: http://www.nature.com/doifinder/https://doi.org/10.1038/sj.jcbfm.9600493.View ArticleGoogle Scholar
- Akaike H. A new look at the statistical model identification. In: Parzen E, Tanabe K, Kitagawa G, editors. Selected Papers of Hirotugu Akaike [Internet]. New York: Springer; 1998. p. 215–22. Available from: http://dx.doi.org/https://doi.org/10.1007/978-1-4612-1694-0_16.Google Scholar
- Wisden W, Laurie DJ, Monyer H, Seeburg PH. The distribution of 13 GABAA receptor subunit mRNAs in the rat brain. I. Telencephalon, diencephalon, mesencephalon. J Neurosci [Internet]. 1992;12(3):1040–62. [cited 2017 Feb 3] Available from: http://www.ncbi.nlm.nih.gov/pubmed/1312131.Google Scholar
- Miederer I, Ziegler SI, Liedtke C, Spilker ME, Miederer M, Sprenger T, et al. Kinetic modelling of [11C]flumazenil using data-driven methods. Eur J Nucl Med Mol Imaging. 2009;36(4):659–70.View ArticlePubMedGoogle Scholar
- Litton JE, Hall H, Pauli S. Saturation analysis in PET—analysis of errors due to imperfect reference regions. J Cereb Blood Flow Metab. 1994;14:358–61.View ArticlePubMedGoogle Scholar
- Salinas C A, Searle GE, Gunn RN. The simplified reference tissue model: model assumption violations and their impact on binding potential. J Cereb Blood Flow Metab [Internet]. Nature Publishing Group; 2015;35(2): 304–11. Available from: http://www.nature.com/doifinder/https://doi.org/10.1038/jcbfm.2014.202
- Amini N, Nakao R, Schou M, Halldin C. Identification of PET radiometabolites by cytochrome P450, UHPLC/Q-ToF-MS and fast radio-LC: applied to the PET radioligands [11C]flumazenil, [18 F]FE-PE2I, and [11C]PBR28. Anal Bioanal Chem. 2013;405(4):1303–10.View ArticlePubMedGoogle Scholar
- Lyoo CH, Ikawa M, Liow J-S, Zoghbi SS, Morse C, Pike VW, et al. Cerebellum can serve as a pseudo-reference region in Alzheimer’s disease to detect neuroinflammation measured with PET radioligand binding to translocator protein (TSPO). J Nucl Med [Internet]. 2015; 701–7. Available from: http://jnm.snmjournals.org/cgi/doi/https://doi.org/10.2967/jnumed.114.146027